Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    BusinessNewsAsia.comBusinessNewsAsia.com
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    BusinessNewsAsia.comBusinessNewsAsia.com
    Home»HealthCare»Novotech Data Shows Majority of AU Sites are Open for Clinical Trial Activity amid COVID-19
    HealthCare

    Novotech Data Shows Majority of AU Sites are Open for Clinical Trial Activity amid COVID-19

    Marie JonesBy Marie JonesApril 9, 2020Updated:April 9, 2020No Comments2 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    SYDNEY – (ACN Newswire) – Novotech has announced that the top 10 biotech sites in Australia were open for clinical trial activity with many sites modifying their practices to ensure continuity of operations. The data contained in the COVID-19 Australia Data Bulletin is part of a new series detailing the current status of trials in the Asia Pacific during the pandemic.

    Low_Novotech200408

    Novotech CEO Dr John Moller said the Bulletin series taps local knowledge of fundamentals in the sector and shows which countries in the region are able to support clinical research for Novotech and its clients during this time.

    “While the situation is always evolving, Australia appears to be managing the crisis well. Our sites have changed how they manage trials in line with Australian Government health guidelines and most are still able to deliver the clinical trial services we need for our clients,” said Dr Moller. “Study delays caused by COVID-19 can be rapidly addressed by activating new sites in Australia and Asia.”

    Australia has attractive start-up times, world-leading investigators and research teams, and valuable rebates of up to 43.5% on clinical trial spend.

    View and Download the COVID-19 Australia Data Bulletin here. https://novotech-cro.com/covid-19-notice

    About Novotech

    Novotech, established in 1996, is internationally recognized as the leading full-service contract research organization (CRO) in Asia-Pacific. Novotech provides clinical development services across all clinical trial phases and therapeutic areas and has been instrumental in the success of over a thousand Phase I – IV clinical trials for biotech companies.

    Novotech obtained the ISO 27001, the best-known standard in the ISO family, providing the requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies. Visit http://novotech-cro.com.

    For RFP enquiries: Please fill out the form available at https://novotech-cro.com/talk-to-an-expert

    Media Contact

    Susan Fitzpatrick-Napier

    communications@novotech-cro.com

    AU: +61 2 8218 2144

    USA: +1 415 951 3228

    Asia: +65 3159 3427

    Novotech
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleAustralian CRO Avance Clinical Designated an Essential Service as Strong Demand from Sponsors Continues Amid COVID-19 Crisis
    Next Article Bityard, World’s Leading Digital Contracts Exchange, has Launched

    Related Posts

    Modern Dental Group Announces 2026 First Quarter Operational Update

    May 29, 2026

    Longbio Pharma Opens Public Offering: Premium Pipeline in Autoimmune & Allergic Diseases Fuels Long-Term Growth

    May 29, 2026

    TR Capital Portfolio Company Pharmacity Raises Growth Capital from LeapFrog Investments

    May 28, 2026
    Add A Comment

    Comments are closed.

    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.